Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Hereditary Angioedema Therapeutic market report explains the definition, types, applications, major countries, and major players of the Hereditary Angioedema Therapeutic market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Takeda Pharmaceutical Company Limited
BIOCRYST PHARMACEUTICALS, INC
CENTOGENE AG
Sanofi
Ionis Pharmaceuticals
KalVista Pharmaceuticals
CSL Limited
Pharming Group NV
Novartis AG
By Type:
Intravenous
Subcutaneous
Oral
By End-User:
Hospitals
Clinics
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Hereditary Angioedema Therapeutic Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Hereditary Angioedema Therapeutic Outlook to 2028- Original Forecasts
-
2.2 Hereditary Angioedema Therapeutic Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Hereditary Angioedema Therapeutic Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Hereditary Angioedema Therapeutic Market- Recent Developments
-
6.1 Hereditary Angioedema Therapeutic Market News and Developments
-
6.2 Hereditary Angioedema Therapeutic Market Deals Landscape
7 Hereditary Angioedema Therapeutic Raw Materials and Cost Structure Analysis
-
7.1 Hereditary Angioedema Therapeutic Key Raw Materials
-
7.2 Hereditary Angioedema Therapeutic Price Trend of Key Raw Materials
-
7.3 Hereditary Angioedema Therapeutic Key Suppliers of Raw Materials
-
7.4 Hereditary Angioedema Therapeutic Market Concentration Rate of Raw Materials
-
7.5 Hereditary Angioedema Therapeutic Cost Structure Analysis
-
7.5.1 Hereditary Angioedema Therapeutic Raw Materials Analysis
-
7.5.2 Hereditary Angioedema Therapeutic Labor Cost Analysis
-
7.5.3 Hereditary Angioedema Therapeutic Manufacturing Expenses Analysis
8 Global Hereditary Angioedema Therapeutic Import and Export Analysis (Top 10 Countries)
-
8.1 Global Hereditary Angioedema Therapeutic Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Hereditary Angioedema Therapeutic Export by Region (Top 10 Countries) (2017-2028)
9 Global Hereditary Angioedema Therapeutic Market Outlook by Types and Applications to 2022
-
9.1 Global Hereditary Angioedema Therapeutic Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Intravenous Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Subcutaneous Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Oral Consumption and Growth Rate (2017-2022)
-
9.2 Global Hereditary Angioedema Therapeutic Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Hereditary Angioedema Therapeutic Market Analysis and Outlook till 2022
-
10.1 Global Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.2.2 Canada Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.2.3 Mexico Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.2 UK Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.3 Spain Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.4 Belgium Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.5 France Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.6 Italy Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.7 Denmark Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.8 Finland Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.9 Norway Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.10 Sweden Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.11 Poland Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.12 Russia Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.3.13 Turkey Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.2 Japan Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.3 India Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.4 South Korea Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.5 Pakistan Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.6 Bangladesh Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.7 Indonesia Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.8 Thailand Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.9 Singapore Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.10 Malaysia Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.11 Philippines Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.4.12 Vietnam Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.5.2 Colombia Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.5.3 Chile Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.5.4 Argentina Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.5.5 Venezuela Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.5.6 Peru Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.5.7 Puerto Rico Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.5.8 Ecuador Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.6.2 Kuwait Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.6.3 Oman Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.6.4 Qatar Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.6.5 Saudi Arabia Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.6.6 United Arab Emirates Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.7.2 South Africa Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.7.3 Egypt Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.7.4 Algeria Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Hereditary Angioedema Therapeutic Consumption (2017-2022)
-
10.8.2 New Zealand Hereditary Angioedema Therapeutic Consumption (2017-2022)
11 Global Hereditary Angioedema Therapeutic Competitive Analysis
-
11.1 Takeda Pharmaceutical Company Limited
-
11.1.1 Takeda Pharmaceutical Company Limited Company Details
-
11.1.2 Takeda Pharmaceutical Company Limited Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Takeda Pharmaceutical Company Limited Hereditary Angioedema Therapeutic Main Business and Markets Served
-
11.1.4 Takeda Pharmaceutical Company Limited Hereditary Angioedema Therapeutic Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 BIOCRYST PHARMACEUTICALS, INC
-
11.2.1 BIOCRYST PHARMACEUTICALS, INC Company Details
-
11.2.2 BIOCRYST PHARMACEUTICALS, INC Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 BIOCRYST PHARMACEUTICALS, INC Hereditary Angioedema Therapeutic Main Business and Markets Served
-
11.2.4 BIOCRYST PHARMACEUTICALS, INC Hereditary Angioedema Therapeutic Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 CENTOGENE AG
-
11.3.1 CENTOGENE AG Company Details
-
11.3.2 CENTOGENE AG Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 CENTOGENE AG Hereditary Angioedema Therapeutic Main Business and Markets Served
-
11.3.4 CENTOGENE AG Hereditary Angioedema Therapeutic Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Sanofi
-
11.4.1 Sanofi Company Details
-
11.4.2 Sanofi Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Sanofi Hereditary Angioedema Therapeutic Main Business and Markets Served
-
11.4.4 Sanofi Hereditary Angioedema Therapeutic Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Ionis Pharmaceuticals
-
11.5.1 Ionis Pharmaceuticals Company Details
-
11.5.2 Ionis Pharmaceuticals Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Ionis Pharmaceuticals Hereditary Angioedema Therapeutic Main Business and Markets Served
-
11.5.4 Ionis Pharmaceuticals Hereditary Angioedema Therapeutic Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 KalVista Pharmaceuticals
-
11.6.1 KalVista Pharmaceuticals Company Details
-
11.6.2 KalVista Pharmaceuticals Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 KalVista Pharmaceuticals Hereditary Angioedema Therapeutic Main Business and Markets Served
-
11.6.4 KalVista Pharmaceuticals Hereditary Angioedema Therapeutic Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 CSL Limited
-
11.7.1 CSL Limited Company Details
-
11.7.2 CSL Limited Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 CSL Limited Hereditary Angioedema Therapeutic Main Business and Markets Served
-
11.7.4 CSL Limited Hereditary Angioedema Therapeutic Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Pharming Group NV
-
11.8.1 Pharming Group NV Company Details
-
11.8.2 Pharming Group NV Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Pharming Group NV Hereditary Angioedema Therapeutic Main Business and Markets Served
-
11.8.4 Pharming Group NV Hereditary Angioedema Therapeutic Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Novartis AG
-
11.9.1 Novartis AG Company Details
-
11.9.2 Novartis AG Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Novartis AG Hereditary Angioedema Therapeutic Main Business and Markets Served
-
11.9.4 Novartis AG Hereditary Angioedema Therapeutic Product Portfolio
-
11.9.5 Recent Research and Development Strategies
12 Global Hereditary Angioedema Therapeutic Market Outlook by Types and Applications to 2028
-
12.1 Global Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Intravenous Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Subcutaneous Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Hereditary Angioedema Therapeutic Market Analysis and Outlook to 2028
-
13.1 Global Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.2.2 Canada Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.2.3 Mexico Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.2 UK Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.3 Spain Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.4 Belgium Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.5 France Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.6 Italy Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.7 Denmark Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.8 Finland Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.9 Norway Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.10 Sweden Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.11 Poland Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.12 Russia Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.3.13 Turkey Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.2 Japan Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.3 India Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.4 South Korea Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.8 Thailand Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.9 Singapore Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.11 Philippines Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.5.2 Colombia Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.5.3 Chile Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.5.4 Argentina Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.5.6 Peru Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.6.3 Oman Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.6.4 Qatar Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.7.2 South Africa Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.7.3 Egypt Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.7.4 Algeria Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Hereditary Angioedema Therapeutic Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Hereditary Angioedema Therapeutic
-
Figure of Hereditary Angioedema Therapeutic Picture
-
Table Global Hereditary Angioedema Therapeutic Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Hereditary Angioedema Therapeutic Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Intravenous Consumption and Growth Rate (2017-2022)
-
Figure Global Subcutaneous Consumption and Growth Rate (2017-2022)
-
Figure Global Oral Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hereditary Angioedema Therapeutic Consumption by Country (2017-2022)
-
Table North America Hereditary Angioedema Therapeutic Consumption by Country (2017-2022)
-
Figure United States Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Canada Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Mexico Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Table Europe Hereditary Angioedema Therapeutic Consumption by Country (2017-2022)
-
Figure Germany Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure UK Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Spain Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Belgium Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure France Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Italy Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Denmark Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Finland Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Norway Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Sweden Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Poland Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Russia Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Turkey Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Table APAC Hereditary Angioedema Therapeutic Consumption by Country (2017-2022)
-
Figure China Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Japan Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure India Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure South Korea Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Thailand Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Singapore Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Philippines Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Table South America Hereditary Angioedema Therapeutic Consumption by Country (2017-2022)
-
Figure Brazil Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Colombia Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Chile Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Argentina Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Peru Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Table GCC Hereditary Angioedema Therapeutic Consumption by Country (2017-2022)
-
Figure Bahrain Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Oman Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Qatar Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Table Africa Hereditary Angioedema Therapeutic Consumption by Country (2017-2022)
-
Figure Nigeria Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure South Africa Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Egypt Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure Algeria Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Table Oceania Hereditary Angioedema Therapeutic Consumption by Country (2017-2022)
-
Figure Australia Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Hereditary Angioedema Therapeutic Consumption and Growth Rate (2017-2022)
-
Table Takeda Pharmaceutical Company Limited Company Details
-
Table Takeda Pharmaceutical Company Limited Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Pharmaceutical Company Limited Hereditary Angioedema Therapeutic Main Business and Markets Served
-
Table Takeda Pharmaceutical Company Limited Hereditary Angioedema Therapeutic Product Portfolio
-
Table BIOCRYST PHARMACEUTICALS, INC Company Details
-
Table BIOCRYST PHARMACEUTICALS, INC Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table BIOCRYST PHARMACEUTICALS, INC Hereditary Angioedema Therapeutic Main Business and Markets Served
-
Table BIOCRYST PHARMACEUTICALS, INC Hereditary Angioedema Therapeutic Product Portfolio
-
Table CENTOGENE AG Company Details
-
Table CENTOGENE AG Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table CENTOGENE AG Hereditary Angioedema Therapeutic Main Business and Markets Served
-
Table CENTOGENE AG Hereditary Angioedema Therapeutic Product Portfolio
-
Table Sanofi Company Details
-
Table Sanofi Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Hereditary Angioedema Therapeutic Main Business and Markets Served
-
Table Sanofi Hereditary Angioedema Therapeutic Product Portfolio
-
Table Ionis Pharmaceuticals Company Details
-
Table Ionis Pharmaceuticals Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ionis Pharmaceuticals Hereditary Angioedema Therapeutic Main Business and Markets Served
-
Table Ionis Pharmaceuticals Hereditary Angioedema Therapeutic Product Portfolio
-
Table KalVista Pharmaceuticals Company Details
-
Table KalVista Pharmaceuticals Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table KalVista Pharmaceuticals Hereditary Angioedema Therapeutic Main Business and Markets Served
-
Table KalVista Pharmaceuticals Hereditary Angioedema Therapeutic Product Portfolio
-
Table CSL Limited Company Details
-
Table CSL Limited Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table CSL Limited Hereditary Angioedema Therapeutic Main Business and Markets Served
-
Table CSL Limited Hereditary Angioedema Therapeutic Product Portfolio
-
Table Pharming Group NV Company Details
-
Table Pharming Group NV Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pharming Group NV Hereditary Angioedema Therapeutic Main Business and Markets Served
-
Table Pharming Group NV Hereditary Angioedema Therapeutic Product Portfolio
-
Table Novartis AG Company Details
-
Table Novartis AG Hereditary Angioedema Therapeutic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis AG Hereditary Angioedema Therapeutic Main Business and Markets Served
-
Table Novartis AG Hereditary Angioedema Therapeutic Product Portfolio
-
Figure Global Intravenous Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Subcutaneous Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hereditary Angioedema Therapeutic Consumption Forecast by Country (2022-2028)
-
Table North America Hereditary Angioedema Therapeutic Consumption Forecast by Country (2022-2028)
-
Figure United States Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Hereditary Angioedema Therapeutic Consumption Forecast by Country (2022-2028)
-
Figure Germany Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Hereditary Angioedema Therapeutic Consumption Forecast by Country (2022-2028)
-
Figure China Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Hereditary Angioedema Therapeutic Consumption Forecast by Country (2022-2028)
-
Figure Brazil Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Hereditary Angioedema Therapeutic Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Hereditary Angioedema Therapeutic Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Hereditary Angioedema Therapeutic Consumption Forecast by Country (2022-2028)
-
Figure Australia Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Hereditary Angioedema Therapeutic Consumption Forecast and Growth Rate (2022-2028)
-
